Expression of co-stimulatory molecules by tumor cells decreases tumorigenicity but may also reduce systemic antitumor immunity

Human Gene Therapy

Volumn 7, Issue 14, 1996, Pages 1771-1779

  Chong, Heung ^a   Hutchinson, Gill ^a   Hart, Ian R ^a   Vile, Richard G ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ARTICLE; CANCER SURGERY; CARCINOGENICITY; CELLULAR IMMUNITY; COLORECTAL TUMOR; CONTROLLED STUDY; GENE EXPRESSION; GENE THERAPY; MELANOMA CELL; MOUSE; NONHUMAN; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR IMMUNITY;

ANIMALIA; MURINAE; MUS MUSCULUS;

EID: 0029818889     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1996.7.14-1771     Document Type: Article

References (55)

1. ALLIONE, A., CONSALVO, M., NANNI, P., LOLLINI, P.L., CAVALLO, F., GIOVARELLI, M., FORNI, M., GULINO, A., COLOMBO, M.P., DELLABONA, P., HOCK, H., BLANKENSTEIN, T., ROSENTHAL, F.M., GANSBACHER, B., BOSCO, M.C., MUSSO, T., GUSELLA, L., and FORNI, G. (1994). Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor α, granulocyte-macrophage colony-stimulating factor and γ-interferon gene or admixed with conventional adjuvants. Cancer Res. 54, 6022-6026.
2. ALTMAN, D.G. (1991). Analysis of survival times. In Practical Statistics for Medical Research. D.G. Altman, ed. (Chapman & Hall, London) pp. 365-395.
3. AZUMA, M., CAYABYAB, M., BUCK, D., PHILLIPS, J.H., and LANIER, L.L. (1992). CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes. J. Exp. Med. 175, 353-360.
4. AZUMA, M., ITO, D., YAGITA, H., OKUMURA, K., PHILLIPS, J.H., LANIER, L.L., and SOMOZA, C. (1993). B70 antigen is a second ligand for CTLA-4 and CD28. Nature 366, 76-79.
5. BASKAR, S., GLIMCHER, L., NABAVI, N., JONES, R., and OSTRAND-ROSENBERG, S. (1995). Major histocompatibility complex class II + B7-1 + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J. Exp. Med. 181, 619-629.
6. BLUESTONE, J.A. (1995). New perspectives of CD28-B7-mediated T cell costimulation. Immunity 2, 555-559.
7. BOON, T., CEROTTINI, J.-C., VAN DEN EYNDE, B., VAN DER BRUGGEN, P., and VAN PEL, A. (1994). Tumor antigens recognised by lymphocytes. Annu. Rev. Immunol. 12, 337-365.
8. CAYEUX, S., BECK, C., AICHER, A., DORKEN, B., and BLANKENSTEIN, T. (1995). Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines. Eur. J. Immunol. 25, 2325-2331.
9. CHEN, L., ASHE, S., BRADY, W.A., HELLSTROM, I., HELLSTROM, K.E., LEDBETTER, J.A., McGOWAN, P., and LINSLEY, P. (1992). Costimulation of antitumor immunity by the B7 counter-receptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71, 1093-11092.
10. CHEN, L., McGOWAN, P., ASHE, S., JOHNSON, J., LI, Y., HELLSTROM, I., and HELLSTROM, K. (1994). Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 179, 523-532.
11. COUGHLIN, C.M., WYSOCKA, M., KURZAWA, H.L., LEE, W.M.F., TRINCHIERI, G., and ECK, S.L. (1995). B7-1 and Interleukin 12 synergistically induce effective antitumor immunity. Cancer Res. 55, 4980-4987.
12. DRANOFF, G., JAFFEE, E., LAZENBY, A., GOLUMBEK, P., LEVITSKY, H., BROSE, K., JACKSON, V., HAMADA, H., PARDOLL, D., and MULLIGAN, R.C. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90, 3539-3543.
13. FRANKS, L., and HEMMINGS, V. (1978). A cell line from an induced carcinoma of mouse rectum. J. Pathol. 124, 35-38.
14. FREEMAN, G.J., GRAY, G.S., GIMMI, C.D., LOMBARD, D.B., ZHOU, L.-J., WHITE, M., FINGEROTH, J.D., GRIBBEN, J.G., and NADLER, L.M. (1991). Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J. Exp. Med. 174, 625-631.
15. FREEMAN, G.J., GRIBBEN, J.G., BOUSSIOTIS, V.A., NG, J.W., RESTIVO, V.A.J., LOMBARD, L.A., GRAY, G.S., and NADLER, L.M. (1993). Cloning of B7-2: A CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262, 909-911.
16. FREEMAN, G.J., BOUSSIOTIS, V.A., ANUMANTHAN, A., BERNSTEIN, G.M., KE, X.-Y., RENNERT, P.D., GRAY, G.S., GRIBBEN, J.G., and NADLER, L.M. (1995). B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 2, 523-532.
17. GIMMI, C.D., FREEMAN, G.J., GRIBBEN, J.G., SUGITA, K., FREEDMAN, A.S., MORIMOTO, C., and NADLER, L.M. (1991). B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc. Natl. Acad. Sci. USA 88, 6575-6579.
18. GRAY, P.W., and GOEDDEL, D.V. (1983). Cloning and expresison of murine immune interferon cDNA. Proc. Natl. Acad. Sci. USA 80, 5842-5846.
19. + cytotoxic T lymphocytes in the absence of exogenous help. J. Exp. Med. 177, 1791-1796.
20. HARDING, F.A., McARTHUR, J.G., GROSS, J.A., RAULET, D.H., and ALLISON, J.P. (1992). CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356, 607-609.
21. HODGE, J., ABRAMS, S., SCHLOM, J., and KANTOR, J. (1994). Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res. 54, 5552-5555.
22. HOUGHTON, A. (1994). Cancer antigens: immune recognition of self and altered self. J. Exp. Med. 180, 1-4.
23. JENKINS, M.K. (1994). The ups and downs of T cell costimulation. Immunity 1, 443-446.
24. KATSANIS, E., XU, Z., BAUSERO, M.A., DANCISAK, B.B., GORDEN, K.B., DAVIS, G., GRAY, G.S., ORCHARD, P.J., and BLAZAR, B.R. (1995). B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules. Cancer Gene Ther. 2, 39-46.
25. KRIPKE, M.L. (1979). Speculations on the role of ultraviolet radiation in the development of malignant melanoma. J. Natl. Cancer Inst. 63, 541-545.
26. KRUMMEL, M.F., and ALLISON, J.P. (1995). CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. Journal of Exp. Med. 182, 459-465.
27. KUCHROO, V.K., DAS, M.P., BROWN, J.A., RANGER, A.M., ZAMVIL, S.S., SOBEL, R.A., WEINER, H.L., NABAVI, N., and GLIMCHER, L.H. (1995). B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy. Cell 80, 707-718.
28. LANE, P., GERHARD, W., HUBELE, S., LANZAVECCHIA, A., and McCONNELL, F. (1993). Expression and functional properties of mouse B7/BB1 using a fusion protein between mouse CTLA4 and human gamma 1. Immunology 80, 56-61.
29. LANIER, L.L., O'FALLON, S., SOMOZA, C., PHILLIPS, J.H., LINSLEY, P.S., OKUMURA, K., ITO, D., and AZUMA, M. (1995). CD80(B7) and CD86(B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J. Immunol. 154, 97-105.
30. LENSCHOW, D., HO, S.C., SATTAR, H., RHEE, L., GRAY, G., NABAVI, N., HEROLD, K.C., and BLUESTONE, J.A. (1995). Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. Journal of Exp. Med. 181, 1145-1155.
31. LEVINE, B.L., UEDA, Y., CRAIGHEAD, N., HUANG, M.L., and JUNE, C.H. (1995). CD28 ligands CD80(B7-1) and CD86(B7-2) induce long-term autocrine growth of CD4+ T cells and induce similar patterns of cytokine secretion in vitro. Int. Immunol. 7, 891-904.
32. LINSLEY, P., BRADY, W., GROSMAIRE, L., ARUFFO, A., DAMLE, N.K., and LEDBETTER, J.A. (1991). Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med. 173, 721-730.
33. LINSLEY, P.S. (1995). Distinct roles for CD28 and cytotoxic T lymphocyte-associated molecule-4 receptors during T cell activation? J. Exp. Med. 182, 289-292.
34. LINSLEY, P.S., and LEDBETTER, J.A. (1993). The role of the CD28 receptor during T cell responses to antigen. Annu. Rev. Immunol. 11, 191-212.
35. MARKOWITZ, D., GOFF, S., and BANK, A. (1988). Construction and use of a safe and efficient amphotropic packaging cell line. Virology 167, 400-406.
36. MORGENSTERN, J.P., and LAND, H. (1990). Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18, 3587-3596.
37. PORGADOR, A., FELDMAN, M., and EISENBACH, L. (1994). Immunotherapy of tumor metastasis via gene therapy. Natural Immun. 13, 113-130.
38. RAMARATHINAM, L., CASTLE, M., WU, Y., and LIU, Y. (1994). T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J. Exp. Med. 179, 1205-1214.
39. RAZI-WOLF, Z., FREEMAN, G.J., GALVIN, F., BENACERRAF, B., NADLER, L., and REISER, H. (1992). Expression and function of the murine B7 antigen, the major costimulatory molecule expressed by peritoneal exudate cells. Proc. Natl. Acad. Sci. USA 89, 4210-4214.
40. SAMBROOK, J., FRITSCH, E.F., and MANIATIS, T. (1989). Molecular Cloning: A Laboratory Manual. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York).
41. SANTODONATO, L., FERRANTINI, M., GABRIELE, L., PROIETTI, E., VENDITTI, M., MUSIANI, P., MODESTI, A., MODICA, A., LUPTON, S.D., and BELARDELLI, F. (1996). Cure of mice with established metastatic Friend leukaemia cell tumors by a combined therapy with tumor cells expressing both interferon-α1 and herpes simplex thymidine kinase followed by ganciclovir. Hum. Gene Ther. 7, 1-10.
42. SETHNA, M.P., PARUS, L.V., SHARPE, A.H., ABBAS, A.K., and FREEMAN, G.J. (1994). A negative regulatory function of B7 revealed in B7-1 transgenic mice. Immunity 1, 415-421.
43. TEPPER, R.I., and MULE, J.J. (1994). Experimental and clinical studies of cytokine gene-modified tumor cells. Hum. Gene Ther. 5, 153-164.
44. THOMPSON, C.B. (1995). Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? Cell 81, 979-982.
45. TIVOL, E.A., BORRIELLO, F., SCHWEITZER, A.N., LYNCH, W.P., BLUESTONE, J.A., and SHARPE, A.H. (1995). Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3, 541-547.
46. TOWNSEND, S.E., and ALLISON, J.P. (1993). Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259, 368-370.
47. TOWNSEND, S., SU, F., ATHERTON, J., and ALLISON, J. (1994). Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res. 54, 6477-6483.
48. VILE, R.G., and HART, I.R. (1993). In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res. 53, 962-967.
49. VILE, R.G., NELSON, J.A., CASTLEDEN, S., CHONG, H., and HART, I.R. (1994). Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. 54, 6228-6234.
50. VILE, R.G., CHONG, H., and DORUDI, S. (1996). The immunosurveillance of cancer: specific and non-specific mechanisms. In Tumor Immunology. A.C. Dalgleish and M.J. Browning, eds. (Cambridge University Press, New York) pp. 7-38.
51. WALUNAS, T.L., LENSCHOW, D.J., BAKKER, C.Y., LINSLEY, P.S., FREEMAN, G.J., GREEN, J.M., THOMPSON, C.B., and BLUESTONE, J.A. (1994). CTLA-4 can function as a negative regulator of T cell activation. Immunity 1, 405-413.
52. WATERHOUSE, P., PENNINGER, J.M., TIMMS, E., WAKEHAM, A., SHAHINIAN, A., LEE, K.P., THOMPSON, C.B., GRIESSER, H., and MAK, T.W. (1995). Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270, 985-988.
53. WU, T.-Z., HUANG, A.Y.C., JAFFEE, E.M., LEVITSKY, H.I., and PARDOLL, D.M. (1995). A reassessment of the role of B7-1 expression in tumor rejection. J. Exp. Med. 182, 1415-1421.
54. YANG, G., HELLSTROM, K.E., HELLSTROM, I., and CHEN, L. (1995). Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J. Immunol. 154, 2794-2800.
55. YEH, K.-Y., PULASKI, B.A., WOODS, M.L., McADAM, A.J., GASPARI, A.A., FRELINGER, J.G., and LORD, E.M. (1995). B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinoma. Cell. Immunol. 165, 217-224.